NCM·Healthcare·$764M·#47 / 520 in Healthcare
GYRE Gyre Therapeutics, Inc.
71SOLID
CATEGORY BREAKDOWN
GROWTH16
QUALITY80
STABILITY100
VALUATION62
GOVERNANCE79
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+10.2%
16
> 50% strong
Gross Margin
Revenue retained after direct costs
95.4%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.9%
99
< 25% strong
Price / Sales
Market cap relative to trailing revenue
6.6x
62
< 3x strong
Rule of 40
Growth rate plus operating margin
20
50
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
81.6%
100
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+10.7%
38
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE GYRE WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when GYRE's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.